Related Experiment Videos
Therapy for cryptococcal meningitis in patients with AIDS
1Division of Infectious Diseases, Washington University School of Medicine, St. Louis, Missouri 63110.
Abstract:
Treatment of cryptococcal meningitis in patients with AIDS with amphotericin B plus flucytosine is associated with a failure rate of 20%-30%. In the absence of chronic suppressive therapy, 40%-60% of patients develop recurrent disease. Recent comparative studies have evaluated fluconazole, a new triazole antifungal agent. In primary therapy, fluconazole is associated with response rates of 35%-60%, which are equivalent to those seen with amphotericin B alone. However, a smaller study suggested that amphotericin B plus flucytosine was superior to fluconazole alone. Both studies identified risk factors associated with a poor outcome; these factors include lethargy or obtundation at presentation, a high titer of cryptococcal antigen titer in the cerebrospinal fluid, and a low leukocyte count in the cerebrospinal fluid. Fluconazole is highly effective in suppressing relapses of cryptococcal meningitis. Itraconazole has been investigated less extensively in the treatment of cryptococcosis but offers promise. Future studies need to address alternative approaches to the management of acute cryptococcal disease and primary prophylaxis for cryptococcal infection in patients with AIDS.
Insights
Cryptococcal meningitis in AIDS patients has high failure and recurrence rates. Fluconazole shows promise for suppression and primary therapy, though amphotericin B plus flucytosine may be superior for acute treatment.
Area of Science:
- Infectious Diseases
- Mycology
- HIV/AIDS Medicine
Background:
- Cryptococcal meningitis is a significant opportunistic infection in patients with Acquired Immunodeficiency Syndrome (AIDS).
- Standard treatment with amphotericin B plus flucytosine has considerable failure (20%-30%) and recurrence (40%-60%) rates without suppressivetherapy.
Purpose of the Study:
- To review and compare the efficacy of fluconazole and other antifungal agents in treating cryptococcal meningitis in AIDS patients.
- To identify risk factors associated with poor outcomes in cryptococcal meningitis treatment.
Main Methods:
- Review of recent comparative studies evaluating fluconazole, a triazole antifungal.
- Analysis of treatment response rates and relapse data for different antifungal regimens.
- Identification of clinical and laboratory parameters predicting treatment failure.
Main Results:
- Fluconazole demonstrates response rates of 35%-60% in primary therapy, comparable to amphotericin B alone.
- Amphotericin B plus flucytosine may be superior to fluconazole monotherapy in acute treatment.
- Fluconazole is highly effective in suppressing relapses of cryptococcal meningitis.
- Poor outcome predictors include lethargy, high cerebrospinal fluid cryptococcal antigen titers, and low cerebrospinal fluid leukocyte counts.
Conclusions:
- Fluconazole is a valuable option for suppressing cryptococcal meningitis relapses in AIDS patients.
- Further research is needed for optimal management of acute disease and primary prophylaxis in this population.
- Itraconazole shows potential but requires more extensive investigation.